Brokers Set Expectations for Gossamer Bio FY2024 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Gossamer Bio in a research note issued on Monday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.18) for the year, up from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million.

Separately, Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Gossamer Bio has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.77 on Wednesday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a fifty day moving average of $0.94 and a 200 day moving average of $0.86. The firm has a market cap of $174.48 million, a PE ratio of -2.42 and a beta of 1.96. Gossamer Bio has a one year low of $0.50 and a one year high of $1.60.

Institutional Investors Weigh In On Gossamer Bio

A number of large investors have recently modified their holdings of GOSS. Acadian Asset Management LLC raised its stake in Gossamer Bio by 51.6% during the first quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after purchasing an additional 931,248 shares during the period. Marshall Wace LLP grew its holdings in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after purchasing an additional 2,103,766 shares in the last quarter. NEA Management Company LLC grew its stake in Gossamer Bio by 14.2% during the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock worth $16,300,000 after purchasing an additional 2,255,025 shares in the last quarter. Monaco Asset Management SAM increased its stake in shares of Gossamer Bio by 390.3% during the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock worth $2,456,000 after buying an additional 2,170,104 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Gossamer Bio by 27.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.